Provention bio announces posting of briefing documents for fda advisory committee meeting on teplizumab

Red bank, n.j., may 25, 2021 /prnewswire/ -- provention bio, inc., (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the u.s. food and drug administration (fda) posted briefing documents for the may 27, 2021 endocrinologic and metabolic drugs advisory committee (emdac) meeting to review the biologics license application (bla) for teplizumab, provention bio's investigational drug candidate for the delay of clinical type 1 diabetes (t1d) in at-risk individuals.
PRVB Ratings Summary
PRVB Quant Ranking